A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.
Phase of Trial: Phase III
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Pramipexole/rasagiline (Primary) ; Pramipexole; Pramipexole; Rasagiline
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Pharma Two B
- 06 Feb 2018 According to a Pharma Two B media release, the first patients have been dosed in this trial.
- 31 Jan 2018 Status changed from not yet recruiting to recruiting.
- 30 Oct 2017 Status changed from planning to not yet recruiting.